Document is current
Any future updates will be listed below
-
Authors
Widdowson, Michael https://orcid.org/0000-0001-9715-568X
Shah, Shiraz
Thorsen, Jonathan https://orcid.org/0000-0003-0200-0461
Poulsen, Casper Sahl
Rosenberg, Julie B.
Mohammadzadeh, Parisa
Jepsen, Jens Richardt Moellegaard
Vinding, Rebecca
Poulsen, Christina Egeø
Rodriguez, Cristina Leal https://orcid.org/0000-0002-3133-0630
Pedersen, Casper-Emil T.
Wang, Tingting
Zachariasen, Trine
Ottosson, Filip
Werge, Thomas Mears
Ernst, Madeleine
Sørensen, Søren Johannes https://orcid.org/0000-0001-6227-9906
Chawes, Bo
Bønnelykke, Klaus
Trivedi, Urvish
Ebdrup, Bjørn H. https://orcid.org/0000-0002-2590-5055
Stokholm, Jakob
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF22OC0073817)
Lundbeckfonden (R269-2017-5)
- License Information
-
More Information
Article History
Received: 20 March 2025
Revised: 30 December 2025
Accepted: 30 January 2026
First Online: 11 February 2026
Competing interests
: JT has received a speaking fee from AstraZeneca. BE is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd; and has received lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company, and Lundbeck Pharma A/S. All authors declare no potential, perceived, or real conflict of interest regarding the content of this manuscript. The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript. No pharmaceutical company was involved in the study.
